Research Progress of Immunotherapy for Brain Metastases in Patients
with Drive Gene Negative NSCLC.
10.3779/j.issn.1009-3419.2018.08.06
- Author:
Shuang ZHANG
1
;
Jingjing LIU
1
;
Changliang YANG
1
;
Shuang LI
1
;
Ying CHENG
1
Author Information
1. Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.
- Publication Type:Journal Article
- Keywords:
Brain metastases;
Driver gene negative;
Immune checkpoint inhibitor;
Lung neoplasms
- MeSH:
Brain Neoplasms;
immunology;
secondary;
therapy;
Carcinoma, Non-Small-Cell Lung;
genetics;
pathology;
Humans;
Immunotherapy;
methods;
Lung Neoplasms;
genetics;
pathology;
Patient Selection
- From:
Chinese Journal of Lung Cancer
2018;21(8):610-614
- CountryChina
- Language:Chinese
-
Abstract:
Brain metastasis was a common metastasis site and leading cause of death in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors had improved survival of NSCLC patients with positive drive gene. It also brings good news to NSCLC patients with positive drive gene and brain metastases. However, there is still no effective treatment for NSCLC patients with drive gene-negative and brain metastases. In recent years, immunotherapy has made breakthrough progress and become important first and second line treatment options of NSCLC especially in patients with drive gene-negative. The role of immunotherapy in specific populations of NSCLC-brain metastasis patients, especially drive gene-negative patients has become the focus of attention. In this report, we review the research progress of immunotherapy in NSCLC with brain metastases, especially in driver-negative patients, analyze the limitations of existing research and future challenge.
.
